Indeed, it has been observed that in vitro cancer cell lines as well as patients with high expression of EGFR ligands, such as amphiregulin (AREG) and epiregulin (EREG), benefit more from Cetuximab therapy [71,72]. The gene discussed is EGFR; the disease is cancer.